Cadent Therapeutics IPO

Developer of a drug development platform intended to focus on medicines for psychiatric diseases. The company's platform develops small molecule therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders, schizophrenia and other cognitive and neuropsychiatric disorders, enabling patients to cure various neurological diseases.

Register for Details

For more details on financing and valuation for Cadent Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Cadent Therapeutics

Forge green plus iconForge green minus icon

What is Cadent Therapeutics funding to date?

Cadent Therapeutics has raised $67.4MM to date.
Forge green plus iconForge green minus icon

When was Cadent Therapeutics founded?

Cadent Therapeutics was founded in 2010.
Updated on: Jun 12, 2022